Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Arcus Biosciences (RCUS) stock falls as Gilead (GILD) decides not to buy rights to its anticancer drug casdatifan. Read more here.

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a ...

Arcus Biosciences (RCUS) announced that Gilead’s (GILD) time-limited exclusive option rights to casdatifan have expired. In addition, Arcus has ...

California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with ...

Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...

BofA lowered the firm’s price target on Arcus Biosciences (RCUS) to $17 from $22 and keeps a Neutral rating on the shares following Gilead’s ...

About the Gilead Collaboration In May 2020, Arcus established a 10-year collaboration with Gilead to strategically advance our portfolio. Under this collaboration, Gilead obtained time-limited ...